Combining dasatinib and quercetin, two established senolytic compounds, produced paradoxical effects when applied to aging human mesenchymal stem cells. While the treatment successfully increased extracellular vesicle secretion and showed promise for new bone formation in mice, it yielded inconsistent results for cellular differentiation into bone and fat cells, along with variable gene and protein expression patterns. This mixed response challenges the straightforward narrative that senolytics universally rejuvenate aged cells. The findings illuminate a critical gap in our understanding of cellular senescence biology—different senescent cell populations may respond heterogeneously to the same intervention. For longevity-focused medicine, this suggests that senolytic therapy may require more personalized approaches rather than one-size-fits-all protocols. The enhanced vesicle secretion could represent beneficial intercellular communication, potentially explaining some anti-aging effects observed in clinical trials. However, the inconsistent differentiation outcomes raise questions about whether clearing senescent stem cells always preserves regenerative capacity. This work underscores that senescence reversal is more complex than simply eliminating damaged cells, requiring nuanced strategies that account for tissue-specific and cell-type-specific responses to therapeutic intervention.